Navigation Links
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
Date:7/7/2009

"would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008; June 30, 2008 and September 30, 2008.

    Contact:
    At the Company:
    Howard J. Leonhardt, Chief Executive Officer
    (954) 835-1500


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
2. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
5. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
6. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
7. Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
8. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
9. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... YORK , Sept. 29, 2014 EU5 ... Summary GlobalData,s new report, "EU5 Capsule ... data on the EU5 Capsule Endoscopy Systems market. The ... (in units) and average prices (in US dollars) within ... and Capsule Endoscopy Workstations. The report also ...
(Date:9/29/2014)... Pharmaceutical Care Management Association (PCMA) President and ... that could reduce prescription fraud and abuse in Medicare ... Opioid Abuse: Fighting Back on Many Fronts ," sponsored ... The briefing featured several government and industry ... fraud. The Centers for Disease Control and Prevention has ...
(Date:9/29/2014)... LAKE CITY , Sept. 29, 2014 /PRNewswire/ ... has scheduled a conference call for investors today ... for the quarter and year ended June 30, ... in participating is (800) 771-7941. Dynatronics ... soft goods and supplies, treatment tables and rehabilitation ...
Breaking Medicine Technology:EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ) today ... on Wednesday, August 3 at 4:30 p.m. Eastern Time to discuss ... follow the release of the second quarter financial results after market ... To access the live conference call on August 3 at ...
... July 27, 2011 For men facing radical prostatectomy ... not their only concern. In fact, a large number of ... continence among their biggest fears. More than 240,000 men will ... patients of Dr. David Samadi,s, Vice Chairman, Department of Urology, ...
Cached Medicine Technology:Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 2Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 3Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 2Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 3
(Date:9/30/2014)... Dennis Thompson HealthDay Reporter ... day, people receive medical implants -- artificial valves, hip ... have been rigorously tested before or after their approval by ... The studies -- conducted by prominent nonprofit groups and ... -- lay the blame for inadequate medical device testing on ...
(Date:9/30/2014)... 30, 2014 Houstonians seeking the latest ... to visit on the Internet. Paul Vitenas, JR. ... respected cosmetic surgeons, has launched a new website to ... of Botox Cosmetic services. The new website ... According to the new website, Botox Cosmetic is a ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Neuromuscular ... people throughout the United States and worldwide. It ... Disease are diagnosed each year, adding to the ... the disease. Approximately 400,000 people in the US ... worldwide. Add to these statistics the 2.4 percent ...
(Date:9/30/2014)... Gummy teeth treatment expert, ... for dark gums. Dark gums are usually considered a ... self-conscious about their smiles. Dr. Farnoosh has pioneered a ... one of the few dental professionals nationwide offering black ... business leaders, high-ranking officials and patients from all over ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Herceptin is the best ... HER2-positive and should remain the standard of care for ... a long-term clinical trial. HER2-positive breast cancers tend ... cancer, according to the Mayo Clinic. For the ... either Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
... (CLP) at Thomas Jefferson University Hospital, recently received an ... scope of the normal duties of serving as ... American College of Surgeons Commission on Cancer (CoC). ... appointment and is among a national network of over ...
... ... Use Dashboard will provide a single location where an organization can see, at a ... ... 2010 -- Health Care DataWorks , a Technology Company created to commercialize the ...
... finds they are equal to artery-clearing surgery, but another ... -- Both stents and conventional surgery appear to be ... arteries are blocked, according to research presented Friday at ... , However, a second stents-versus-surgery trial, published Thursday in ...
... ... company, has signed a strategic partnership agreement with Medical Insight to complete the ... capability across the healthcare enterprise. , , ... Milwaukee (PRWEB) February 26, 2010 -- ...
... The natural-occurring biopolymer known as chitosan is being put ... the diet of ruminants, according to research carried out ... presence of these antibiotics as additives in the diet ... since 2006, given that their use is linked to ...
... ... ... ... ...
Cached Medicine News:Health News:Jefferson surgeon receives outstanding performance award from American College Of Surgeons 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2Health News:Stents May Be Effective Weapon Against Stroke 2Health News:Stents May Be Effective Weapon Against Stroke 3Health News:Stents May Be Effective Weapon Against Stroke 4Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 2Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 3Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 2Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 2Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 4Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 5
Manufactured with large, shatter-resistant Clear Pb leaded acrylic panels which provide a wide field of vision for one or more users. Opaque lower panels are covered in your choice of decorative viny...
... Excellent for patient protection ... erect chest and cervical spine. ... 0.5mm shield. Height adjustable 36" ... sturdy star-leg aluminum base for ...
RayShield Frame Mounted Overhead Lead Acrylic Barriers are offered in a choice of three sizes: 60 cm x 80 cm ( 24" x 32") wide, 60 cm x 50 cm( 24" x 20") wide. Lead acrylic windows of 0.5 mm and 1.0 ...
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre...
Medicine Products: